Article
Interindividual variations in metabolism and pharmacokinetics of 3-(6-methylpyridine-3-yl-sulfanyl)-6-(4H-[1,2,4]triazole-3-yl-sulfanyl)-N-(1,3-thiazole-2-yl)-2-pyridine carboxamide, a glucokinase activator, in rats caused by the genetic polymorphism of CYP2D1.
Drug metabolism and disposition: the biological fate of chemicals - 1 Sept 2014
Hasegawa Takuro, Eiki Jun-ichi, Chiba Masato
Abstract excerpt
3-(6-Methylpyridine-3-yl-sulfanyl)-6-(4H-[1,2,4]triazole-3-yl-sulfanyl)-N-(1,3-thiazole-2-yl)-2-pyridine carboxamide (Cpd-D) is a novel glucokinase activator that is being developed for the treatment of type 2 diabetes. Large interindividual variations were observed in the pharmacokinetics of Cpd-D in male Sprague-Dawley (SD) rats, which were subsequently divided into two phenotypes; >6-fold longer terminal-phase...
Topics
- Administration, Oral
- Alcohol Oxidoreductases
- Alleles
- Animals
- Area Under Curve
- Bile
- Cytochrome P-450 Enzyme System
- Cytochrome P450 Family 2
- Genetic Association Studies
- Glucokinase
- Half-Life
- Male